Business Context and Reporting Period
This Form 8-K was filed by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc.) on April 29, 2021. The filing serves as a Regulation FD disclosure regarding the announcement of topline results from the KARE Phase 2 dose-ranging clinical trial of Oral KORSUVA (difelikefalin tablets) for the treatment of moderate-to-severe pruritus in patients with mild-to-severe atopic dermatitis (AD).
Key Financial Metrics
This filing is a current report focused on clinical trial results and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Clinical Results
The filing details the outcomes of the KARE Phase 2 trial involving 401 adult subjects randomized to receive 0.25 mg, 0.5 mg, or 1 mg of Oral KORSUVA twice daily versus placebo.
- Primary Efficacy Endpoint: No dose group met the primary endpoint (change from baseline in weekly mean daily 24-hour Itch NRS score at week 12) for the overall population. However, the 1 mg dose showed statistically significant improvement from baseline as early as week 1, sustained through 75% of the treatment period.
- Subgroup Analysis: In a prespecified analysis of the mild-to-moderate (BSA<10%) patient population, a statistically significant change in the primary endpoint was observed (p=0.036).
- Key Secondary Endpoint: No dose group met the 4-point Responder Analysis endpoint for the Intent-to-Treat (ITT) population. However, in the mild-to-moderate subgroup, 32% of KORSUVA-treated patients achieved a ≥4 point reduction versus 19% in the placebo group (p=0.033). The 0.5 mg dose specifically showed statistical significance (p=0.046).
- Safety: Oral KORSUVA was generally well-tolerated. Common adverse events included abdominal pain, nausea, dry mouth, headache, dizziness, and hypertension. Hypertension was noted in 5/77 patients in the 1 mg group, with 4/5 having a prior history of the condition.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or long-term strategic outlook beyond the immediate clinical results. The primary risk highlighted is the failure of the overall study population to meet the primary and key secondary efficacy endpoints, though positive signals were identified in the mild-to-moderate disease severity subgroup. The company noted that the sample size for the 0.5 mg and placebo groups was increased by approximately 60% based on an interim conditional power assessment.
Investor Verification Checklist
- Verify the distinction between the overall study population results (negative for primary endpoint) and the mild-to-moderate subgroup results (positive).
- Review the full press release (Exhibit 99.1) and presentation (Exhibit 99.2) for detailed statistical data not fully summarized in the 8-K text.
- Assess the safety profile regarding hypertension, particularly in the 1 mg dose group, and its potential impact on future dosing strategies.
- Confirm the company's next steps regarding the development of Oral KORSUVA given the mixed results.